Table 4 Serum and CSF biomarkers concentrations at different time points compared to baseline (first Tofersen administration).

From: Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen

Biomarker

T0, median (IQR)

N T3

T3, median (IQR)

p-value (T3 vs T0)

N T6

T6, median (IQR)

p-value (T6 vs T0)

p-value (T6 vs T3)

N T9

T9, median (IQR)

p-value (T9 vs T0)

p-value (T9 vs T6)

N T12

T12, median (IQR)

p-value (T12 vs T0)

p-value (T12 vs T9)

N T15

T15, median (IQR)

p-value (T15 vs T0)

p-value (T15 vs T12)

N T18

T18, median (IQR)

p-value (T18 vs T0)

p-value (T18 vs T15)

Serum NfL, pg/ml

55.35 (33.15–90.45)

14

46.4 (36.9–55.2)

0.07

9

34 (22.8–64.9)

0.69

0.31

13

39.6 (18.8–52.2)

0.083

0.31

13

24.6 (17–55.5)

0.52

0.43

10

15.95 (10.6–36.4)

0.16

0.008

4

18.8 (12.83–23.05)

1.00

0.75

CSF NfL, pg/ml

3520 (2486–4644)

18

2748 (1756–5118)

0.031

18

2368 (1416–3598)

0.021

0.016

18

1941 (1433–3162)

0.027

0.47

15

2047 (1729–4473)

0.27

0.06

11

1968 (1063–2799)

0.06

0.76

7

2153 (978–3050)

0.16

0.30

Serum NfH, pg/ml

912.5 (442.5–1867.5)

12

961 (526.5–1731.5)

0.20

7

655 (431–953)

0.06

0.31

11

648 (495–1046)

0.25

1.00

10

714 (563–1046)

0.84

0.25

9

551 (463–656)

0.19

0.09

4

849.5 (510–964)

1.00

1.00

CSF NfH, pg/ml

4560 (2498–6333)

15

3709 (1674–7356)

0.004

15

2562 (1552–5279)

0.008

0.52

15

2751 (1350–5437)

0.22

0.92

12

2784 (1511–6154.5)

0.52

0.79

9

2476 (1318–3703)

0.15

0.20

7

1400 (1165–3736)

0.06

0.30

Serum SerpinA1, μg/ml

844.49 (642.32–987.09)

13

1098.13 (777.017–1687.78)

0.34

9

666.95 (554.2–862.015)

0.73

0.20

11

899.24 (585.23–1044.84)

0.70

0.69

11

1522.889 (1193.65–1705.89)

0.16

0.012

8

1300.48 (1014.46–1638.70)

0.19

0.94

3

1619.21 (664.72–1791.66)

1.00

0.50

CSF SerpinA1, μg/ml

1.71 (1.06–3.24)

17

2.69 (1.66–4.38)

0.06

17

2.99 (2.46–8.12)

0.011

0.06

17

5.25 (2.82–12.39)

 < 0.001

0.35

12

7.87 (3.30–12.77)

 < 0.001

0.13

9

8.89 (3.52–12.93)

0.004

0.30

6

23.41 (18.36–45.51)

0.003

0.17

Serum CHI3L1, ng/ml

37.62 (31.99–126.67)

13

41.43 (31.03–52.07)

0.28

9

39.70 (30.52–124.61)

0.17

0.25

13

47.23 (34.01–69.58)

0.032

0.50

11

44.04 (31.99–128.61)

0.43

0.50

8

54.59 (46.61–86.40)

0.44

0.58

3

54.83 (18.62–62.50)

1.00

1.00

CSF CHI3L1, ng/ml

83.26 (50.22–105.20)

17

74.98 (49.71–94.92)

0.98

17

88.99 (50.44–122.03)

0.58

0.35

17

79.24 (53.62–130.65)

0.82

0.93

13

113.71 (99.35–130.91)

0.007

0.06

9

157.68 (102.89–213.34)

0.008

1.00

6

170.31 (77.95–215.33)

0.09

0.69

  1. Median values with interquartile ranges were reported. p-values refer to matched-pairs comparisons for each subject between each time point (at three (T3), six (T6), nine (T9), twelve (T12), fifteen (T15) and eighteen (T18) months after baseline) and baseline (T0). Given the non-normal, left-skewed distribution of all biomarkers, the Wilcoxon matched-paired sign-rank test was used to test for the equality of matched pairs of observations. Statistically significant p-values are reported in bold character. CHI3L1, chitinase 3 like-1; CSF, cerebrospinal fluid; IQR, interquartile ranges; NfH, neurofilament heavy chain; NfL, neurofilament light chain.
Back to article page